Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from INVO Fertility ( (IVF) ).
On June 30, 2025, NAYA Therapeutics Inc. amended its Securities Purchase Agreement with an institutional investor, allowing the investor to purchase additional shares of Series C-2 Convertible Preferred Stock or exchange them for a portion of the company’s debenture. This amendment aims to provide flexibility in investment options and potentially impact the company’s financial structure and market positioning. Additionally, the company entered into an AIR Exercise and Reload Agreement, resulting in the issuance of new unregistered C-2 Preferred shares and restrictions on certain stock transactions for a specified period, which could influence the company’s stock issuance strategy and shareholder value.
The most recent analyst rating on (IVF) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Underperform.
The overall stock score reflects significant financial and technical challenges. The company’s financial performance is marred by losses and high leverage, while technical indicators signal negative momentum. Additionally, valuation metrics highlight market concerns about future profitability.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
Average Trading Volume: 2,460,876
Technical Sentiment Signal: Sell
Current Market Cap: $1.98M
See more data about IVF stock on TipRanks’ Stock Analysis page.